Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Recommendation of "Buy" from Analysts

Key Points

• Ascendis Pharma A/S has received a consensus rating of "Buy" from 15 different analysts, indicating strong market confidence in the stock's potential.
• The average 12-month price target for Ascendis Pharma A/S is $223.07, suggesting significant upside from its current trading price.
• Despite reporting a earnings per share of ($1.66) which missed expectations, the company's revenue for the quarter was $123.97 million, exceeding analysts' forecasts.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has received an average recommendation of "Buy" from the fifteen analysts that are covering the company, Marketbeat.com reports. Fifteen investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $223.67.

A number of research analysts recently weighed in on the company. Citigroup raised their price objective on Ascendis Pharma A/S from $213.00 to $243.00 and gave the company a "buy" rating in a research note on Friday, July 11th. Royal Bank Of Canada raised their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 target price on shares of Ascendis Pharma A/S in a report on Monday, May 12th. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $245.00 to $254.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, Oppenheimer reissued an "outperform" rating and set a $224.00 price objective (up previously from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th.

Ascendis Pharma A/S Stock Up 4.0%

Shares of ASND traded up $6.67 during midday trading on Monday, reaching $173.45. 232,897 shares of the stock were exchanged, compared to its average volume of 482,237. Ascendis Pharma A/S has a 12-month low of $111.09 and a 12-month high of $183.00. The firm has a 50 day simple moving average of $170.92 and a 200-day simple moving average of $156.33. The company has a market cap of $10.61 billion, a price-to-earnings ratio of -27.73 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million. Research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Institutional investors have recently bought and sold shares of the business. HighTower Advisors LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $484,000. Corient Private Wealth LLC bought a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $450,000. LPL Financial LLC raised its position in shares of Ascendis Pharma A/S by 60.1% during the fourth quarter. LPL Financial LLC now owns 4,199 shares of the biotechnology company's stock worth $578,000 after acquiring an additional 1,577 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Ascendis Pharma A/S by 94.4% during the fourth quarter. JPMorgan Chase & Co. now owns 77,427 shares of the biotechnology company's stock worth $10,659,000 after acquiring an additional 37,593 shares during the last quarter. Finally, New Age Alpha Advisors LLC bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at about $507,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.